Executive Profiles

Spiro Rombotis, president and CEO of Cyclacel, highlights why targeting cyclin-dependent kinases and the DNA repair pathway could improve the standard of care across multiple oncology indications.

Shawn Singh, CEO of VistaGen Therapeutics’, discusses the company’s pipeline of new generation drug candidates for depression, neuropathic pain, Parkinson’s dyskinesia, social anxiety disorder, and suicidal ideation with potential for convenient, at-home use, rapid-onset therapeutic benefits, and exceptional safety.

Amicus Therapeutics CEO John Crowley, whose biotech journey and quest to cure two of his kids of a rare genetic disease is well chronicled, discusses the growing role of the patient-centered view in company culture-not just in adding “deeper meaning” to drug development, but in building patient advocacy into everyday business practice and strategy.

In this Q&A, Athersys CEO, Gil Van Bokkelen, PhD, discusses his perspective on the recent advancements in stem cell therapies.

A Q&A that discusses challenges of biopharmaceutical entrepreneurship in the oncology indication and the opportunities for successful therapeutic development.

Jean Drouin M.D., CEO of Clarify Health Solutions, gives Pharm Exec his perspective on how biopharmaceutical companies are faring in the use of AI and machine learning

The next Q&A in the HBSHAA series, Career Insights for 2020, Michael Wong interviews Caitlin Hadtke Gagnon from J&J.

Scott Williams, Merck KGaA, Darmstadt, Germany’s Vice President, Head of Global Patient Advocacy and Strategic Partnerships, talks about the Embracing Carers initiative’s objectives and how its success is being measured.

Health care companies going public were reported at record levels last year, with pharma and biotech firms leading the way.

An interview with Brian Zietsman, CFO of Enteris, to discuss his strategy and how it is diversifying drug development risk, and increasing valuation.

Dr. Lingshi Tan, a director at DIA, and chairman and CEO of Shanghai-based CRO dMed Company Limited, which he founded after establishing R&D operations for Pfizer in China, discusses the nation's regulatory evolution and opportunities for its government to strengthen collaborations with FDA and other leading global agencies.

Pharm Exec profiles Dr. Xiaobin Wu, an accomplished leader in helming China operations at big pharmas such as Pfizer and Bayer, who believes his recent jump to biotech as GM of China and president of BeiGene will deliver his most lasting legacy.

Kilian Weiss, Veeva Oncology Link General Manager, talks about how the Oncology Link offering has evolved and how it facilitates the process of identifying and approaching key opinion leaders.

A discussion of why healthcare is still an attractive career industry choice and the top career recommendations for the next decade.

Excerpts resulting from the extended discussion on CRO oversight at the recent CBI Finance and Accounting for Bioscience Companies conference.

Rick Krohn talks to Pharm Exec about the pharma applications of one of tech’s hottest solutions – blockchain.

In this Q&A, American-born David Meek, today CEO of Paris-based multinational Ipsen, discusses the drugmaker's bold global expansion and R&D transformation-driven by revamped leadership, a biotech mindset, and promoting external innovation.

Leaders at Novartis share how the big pharma is laying the foundations for a potential new operating model as a "medicines and data science company."

As part of its digital transformation, last year Novartis recruited Raj Patil, as Head of Data Strategy, and Shahram Ebadollahi as Head of Data Science and Advanced Analytics. Here they talk to Pharm Exec about the task that lies ahead.

How patient support programs have changed over the past two decades, considering adding safety data collection to the mix, and what regulations are driving pharma to adopt pharmacovigilance.

Andre Heeg, Sandor's new Head of Digital, tells Pharm Exec about his digital vision for the company.

Hilary Hutton-Squire, Gilead’s UK & Ireland General Manager, talks to Pharm Exec about the company's new "HIV Age Positively" campaign.

Pharm Exec speaks to Mark Lambrecht, Director of the Health and Life Sciences Global Practice at SAS, about the growing role of big data analytics in pharma and how the industry is evolving to keep pace with it.

Michael Wong talks to Pharm Exec about the takeaways from November's Harvard Business School Healthcare Alumni Association conference on how AI can successfully deliver value for pharma companies.

Ablexis licenses the AlivaMab Mouse, a transgenic mouse that “dramatically improves upon other antibody discovery platforms”. CEO Larry Green tells PharmExec about the evolution of the company and the main challenges associated with the pre-clinical discovery of monoclonal antibodies.

Anjum Swaroop, Vice President and Head of IP at Dr. Reddy's, talks to Pharm Exec about her journey with the company and about what the future holds for this major US generics player.

As this year's ESMO gets under way, Pharm Exec spoke to James Campbell-global franchise business head at Merck KGaA, Darmstadt, Germany-to discuss his vision for the company as a global leader in oncology.

Pharm Exec speaks to Inovio Pharmaceutical's Dr. J. Joseph Kim about his journey from humble beginnings as an 11-year-old Korean immigrant to his present position at the forefront of a new medical frontier.

Pharm Exec talks with CSL Limited’s top executive about the realities of running the global, Australian-headquartered specialty biotech company and sustaining a strong focus in a fast-encroaching era of disruptive technologies and new priorities in innovation and R&D.

Pharm Exec talks to AELIX Therapeutics' Dr. José Luis Cabero about how the major career and country shift he made a decade ago have motivated and sustained a new direction in his career.